Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-1 Antibodies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT05732662
What this trial is testing

SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC

Who this might be right for
Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
The First People's Hospital of Changzhou 25
Not applicableLooking for participantsNCT04324125
What this trial is testing

Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Hunan Province Tumor Hospital 70
Testing effectiveness (Phase 2)Active Not RecruitingNCT04833387
What this trial is testing

PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer

Who this might be right for
Colorectal Carcinoma
Sun Yat-sen University 30
Early research (Phase 1)Looking for participantsNCT07027514
What this trial is testing

Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Ankyra Therapeutics, Inc 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT05468138
What this trial is testing

PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery

Who this might be right for
MSI-HPD-1 ImmunotherapyGastric Cancer+1 more
Fudan University 94
Large-scale testing (Phase 3)Ended earlyNCT03348904
What this trial is testing

Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Incyte Corporation 2
Very early researchNot Yet RecruitingNCT07172178
What this trial is testing

Γδ T-PD-1 Ab Cells in the Treatment of Malignant Meningioma

Who this might be right for
Malignant Meningioma
Nanjing Medical University 12
Testing effectiveness (Phase 2)UnknownNCT05430906
What this trial is testing

AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer

Who this might be right for
Ovarian Cancer
Hunan Cancer Hospital 40
Testing effectiveness (Phase 2)Study completedNCT03187314
What this trial is testing

Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer

Who this might be right for
Esophageal NeoplasmsEsophageal DiseasesEsophageal Squamous Cell Carcinoma
Hangzhou Cancer Hospital 25
Testing effectiveness (Phase 2)Study completedNCT05025033
What this trial is testing

Chemotherapy Combined With Apatinib and PD-1 Antibody

Who this might be right for
Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)WithdrawnNCT03746249
What this trial is testing

Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC

Who this might be right for
Hepatocellular Carcinoma
Sun Yat-sen University
Testing effectiveness (Phase 2)UnknownNCT06424821
What this trial is testing

Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC

Who this might be right for
NSCLC
Shanghai Pulmonary Hospital, Shanghai, China 54
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06567600
What this trial is testing

Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma

Who this might be right for
Intrahepatic CholangiocarcinomaChemotherapy EffectImmunotherapy
Third Affiliated Hospital, Sun Yat-Sen University 43
Testing effectiveness (Phase 2)UnknownNCT04797507
What this trial is testing

SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer

Who this might be right for
SHR-1210AnlotinibAdvanced Esophageal Squamous Cell Cancer
Peking Union Medical College Hospital 33
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06916416
What this trial is testing

Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma

Who this might be right for
Classical Hodgkin Lymphoma
University of Cologne 50
Early research (Phase 1)Study completedNCT05116007
What this trial is testing

Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC

Who this might be right for
SCLC, Extensive Stage
Akeso 35
Testing effectiveness (Phase 2)Study completedNCT01968109
What this trial is testing

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Who this might be right for
Neoplasms by Site
Bristol-Myers Squibb 1,482
Testing effectiveness (Phase 2)UnknownNCT05675033
What this trial is testing

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

Who this might be right for
Lung AdenocarcinomaStage IV Non-small Cell Lung CancerPD-1 Inhibitor+1 more
Fujian Cancer Hospital 50
Testing effectiveness (Phase 2)Temporarily pausedNCT04084158
What this trial is testing

Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.

Who this might be right for
Esophageal Squamous Cell Carcinoma
Zhejiang Cancer Hospital 100
Testing effectiveness (Phase 2)UnknownNCT03631615
What this trial is testing

Neoadjuvant Chemoradiation Plus PD-1 Antibody(SHR-1210) in Locally Advanced Proximal Stomach Adenocarcinoma

Who this might be right for
Gastric Adenocarcinoma
Shanghai Zhongshan Hospital 36
Next Page